Eur Rev Med Pharmacol Sci 2018; 22 (22): 7704-7709
DOI: 10.26355/eurrev_201811_16391

Clinicopathologic and prognostic relevance of miR-1256 in colorectal cancer: a preliminary clinical study

Z.-Y. Liu, L. Yang, H.-Y. Chang

Department of Gastroenterological Surgery, Jining No.1 People’s Hospital, Jining, Shandong, China. chhioaa61@126.com


OBJECTIVE: MicroRNAs (miRNAs) as a new class of biomarkers have been explored in recent studies. We investigate whether miR-1256 could be considered as powerful biomarkers for predicting the prognosis of colorectal cancer (CRC).

PATIENTS AND METHODS: The expression of miR-1256 in CRC was compared with matched normal tissue and using qRT-PCR. The correlation of miR-1256 expression with clinicopathological factors was statistically analyzed. Survival rate was determined with Kaplan-Meier and statistically analyzed with the log-rank method between groups. Univariate and multivariate Cox regression analysis was used to identify the independent risk factors for CRC.

RESULTS: We found that miR-1256 level in CRC tissues is notably reduced compared to matched non-cancerous specimens (p < 0.01), and the expression of miR-1256 was significantly correlated with TNM stage (p = 0.000) and lymph node metastasis (p < 0.07). Kaplan-Meier analysis showed that CRC patients with low miR-1256 expression level had distinctly shorter overall survival (p = 0.004) and disease-free survival (p < 0.001) than patients with high miR-1256 expression level. Finally, Cox regression analyses showed that low miR-1256 expression might be an independent prognostic parameter to predict poor prognosis of CRC patients.

CONCLUSIONS: We firstly provided evidence that low miR-1256 expression was associated with the progression of CRC and could be used as a prognostic biomarker for breast cancer. Further studies are needed.

Free PDF Download

To cite this article

Z.-Y. Liu, L. Yang, H.-Y. Chang
Clinicopathologic and prognostic relevance of miR-1256 in colorectal cancer: a preliminary clinical study

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 22
Pages: 7704-7709
DOI: 10.26355/eurrev_201811_16391